- Home
- BBOT vs IOVA Comparison
BBOT vs IOVA Comparison
Compare BBOT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBOT | IOVA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 968.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BBOT | IOVA |
|---|---|---|
| Price | $13.69 | $2.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $23.80 | $10.36 |
| AVG Volume (30 Days) | 168.9K | ★ 12.8M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $250,425,000.00 |
| Revenue This Year | N/A | $60.94 |
| Revenue Next Year | N/A | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $8.50 | $1.64 |
| 52 Week High | $14.78 | $9.30 |
Technical Indicators
Market Signals| Indicator | BBOT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.00 |
| Support Level | N/A | $2.13 |
| Resistance Level | N/A | $2.55 |
| Average True Range (ATR) | 0.00 | 0.16 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 23.58 |
Price Performance
Historical ComparisonAbout BBOT BridgeBio Oncology Therapeutics Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.